MedTrace Logo

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

NCT06663111 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-10-29

No results posted yet for this study

Summary

ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

OTHER

Blood samples for PK

Blood sampled for pharmacokinetic study

OTHER

Blood samples for PK

Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.

Sponsors & Collaborators

  • University of Bergen

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Trond T. Serkland, M.D. · Haukeland University Hospital

  • Silje Skrede, M.D., PhD · University of Bergen

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06663111 on ClinicalTrials.gov